MRK241213P117000
- 0.00
- 0.000.00%
Merck & Co Newsroom
CITIC Securities: Maintain the "Outperform Industry" rating for He Yu-B with a Target Price of HKD 6.76.
CICC released a research report stating that it maintains the forecast for Haoyu-B (02256) parent Net income for 2024 and 2025 at 2.13 million RMB and 2.7 million RMB unchanged. According to the DCF model, the bank maintains an outperform rating for the Industry and a Target Price of 6.76 HKD. On December 8, the company announced that it reported the preliminary phase II study results of Pimicotinib (ABSK021) for the treatment of 2L+ chronic graft-versus-host disease (cGvHD) at the 66th American Society of Hematology (ASH) annual meeting. Although most enrolled patients have not completed cGvHD relief.
Trump is reportedly set to ring the bell at the NYSE today. What does it signify?
① According to media reports, the USA's incoming president Trump will go to the NYSE on Thursday to ring the opening bell and deliver a speech; ② There are reports that Trump will be named Time Magazine's Person of the Year for 2024, but this has not yet been confirmed by Time; ③ Since Trump's announcement of victory, the three major US stock indices have risen repeatedly, with the market encouraged by promises of tax cuts and deregulation.
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $121
Express News | Lynparza® (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in Olympia Phase 3 Trial
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $121
Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Dow Down 150 Points On Losses For Shares Of Caterpillar, 3M
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
Today's Analyst Rating | Tesla Price Target Raised to $400 by Morgan Stanley, Oracle Price Target Raised to $194 by Citi
Express News | B of A Securities Reinstates Buy on Merck & Co, Announces $121 Price Target
Merck & Co Analyst Ratings
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125